
AZ and Amgen jointly develop and sell five inflammation therapies
Executive Summary
AstraZeneca PLC, its biologics arm MedImmune LLC, and Amgen Inc. have agreed to jointly develop and commercialize five of Amgen’s clinical-stage monoclonal antibodies: AMG139, AMG157, AMG181, AMG557, and brodalumab (AMG827).
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com